Psychopharmacology

How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.

Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.

How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.

Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.

Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.

Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.

Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.

Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.

Check out our pipeline updates from September!

Learn why ketogenic metabolic therapy is a monitored medical treatment, not a fad diet, and how metabolic pathways may reshape mental health care.

A cross-sector ACNP task force calls for shared standards and shared data to move psychiatry beyond trial-and-error prescribing.

New evidence links hippocampal “internally generated” activity to memory and psychosis, suggesting new network-based models for schizophrenia.

Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.

Xanomeline-trospium targets muscarinic receptors for schizophrenia relief with fewer side effects, and early data suggest cognitive gains.

Cobenfy revived shelved muscarinic therapy for schizophrenia, easing side effects while boosting negative and cognitive symptoms across trials.

Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.

Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.

Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.

Experts urge caution prescribing GLP-1s for patients with eating disorders, highlighting motivation checks, psychoeducation, and team-based care.

GLP-1 weight-loss drugs may aid binge eating, but clinicians must screen for eating disorders and monitor patients with multidisciplinary care.

Learn how to launch TMS or Spravato services—costs, billing, REMS logistics, training, and what’s next in interventional psychiatry.

After 2 antidepressant trials, TMS or esketamine offers faster relief and durable remission—see why clinicians switch sooner.

A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.

Potential anti-anxiety agent SNTX-2643 blunted the brain's stress response for 24 hours, with no dissociative or abuse-related effects.

Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.